Thermo Fisher Scientific supplies instruments, reagents and contract development and manufacturing services to the life-science and clinical markets; market capitalization is roughly $239.8 billion and the company sits squarely in the Life Science Tools & CDMO theme. Institutional ownership is unusually high, with about 94.1% of shares held by reporting institutions and 3,571 reporting holders, which concentrates stewardship and keeps the stock tightly owned.
Revenue trends shifted from flattish and slightly negative year-over-year comparisons in 2023–2024 to consistent growth starting in early 2025 and accelerating through 2026. Quarterly revenue rose to $11.994 billion in CY2026Q2, a 10.5% year-over-year gain, and the series shows revenue acceleration as the most recent quarters delivered progressively stronger YoY gains. GAAP diluted EPS has generally risen over the same period — most recently $4.68 in CY2026Q2, about a 9.3% YoY increase — but EPS acceleration is not as consistent as revenue acceleration.
The theme context matters because demand for tools and CDMO services tends to track R&D and biomanufacturing investment; Thermo Fisher’s recent revenue acceleration, above-market relative strength and institutional sponsorship position it as a leader within that theme. The scorecard flags the company with a 62.5 leader-selection score, six of seven trend checks passed, and six-month excess return versus the S&P 500 well above target, all of which reinforce the view of sector leadership while also leaving room for typical industry cyclicality.
Why now
Revenue growth has re-accelerated into double-digit year-over-year gains (CY2026Q2 +10.5%), the stock is materially outperforming the S&P 500 (three-month excess return +36.7%), and institutional ownership sits near 94%, so the company’s operating momentum and concentrated sponsorship make it timely to watch for theme exposure.
The setup
Price closed at $648.43 on 2026-09-16, trading above the 50-day (585.40) and 200-day (537.26) simple moving averages and above the 9- and 21-day EMAs (623.02 and 613.44). Six of seven trend checks are satisfied and 50-day up/down volume ratio is 1.56, but Weinstein stage is listed as Stage 3 — topping — and the long average has stopped rising (the 150-day/200-day check failed). Entry-readiness is flagged as "watch": there is no verified fresh breakout or 9/21-EMA add setup and the stock sits about 4.1% above the 9-day EMA.
Revenue trajectory
Full-year revenue with year-over-year growth. Solid bars are calendar-year actuals from SEC EDGAR filings (XBRL); dashed bars are analyst consensus via Yahoo Finance (26 analysts), which is published two fiscal years out.Earnings trajectory
Solid bars are quarterly GAAP diluted EPS from SEC EDGAR filings. Dashed bars are analyst consensus, which is typically adjusted (non-GAAP). The two are measured differently, so a step between the last actual and the first estimate usually reflects that change in basis rather than a change in the business.Analyst full-year EPS consensus (typically adjusted): FY'26E $25.13 (+10%) · FY'27E $27.53 (+10%) — 26 analysts
Risks
Revenue momentum could slow if R&D and biomanufacturing spending softens, since the business is tied to cyclical industry investment. GAAP diluted EPS has not shown consistent acceleration in line with revenue, creating the risk of margin or execution variability. High institutional concentration (about 94% held) can reduce float liquidity and amplify price moves if large holders rebalance.
Framework fit
CANSLIM
5/7- CCurrent quarterly GAAP EPS growth ≥ 25%+9%✕
- AAnnual GAAP EPS growth ≥ 25%+7%✕
- NNew highs — within 15% of 52-week high0%✓
- SSupply/demand — up-day volume leads1.56x✓
- LLeader — outperforming the S&P 500+25% 6m✓
- IInstitutional sponsorshipmodel score 8/10✓
- MMarket in a confirmed uptrendConfirmed uptrend✓
Minervini Trend Template
6/7Stage 2 confirmation checklist: price versus rising long-term moving averages and the 52-week range.
Weinstein Stage
Price is near or above the 30-week proxy, but the long average has stopped rising.